References

  1. https://adisinsight.springer.com/
  2. https://finance.yahoo.com/sectors/healthcare/articles/bain-backed-tanabe-pharma-targets-003551630.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIeyTDKUk5iS_xrYc0CXmkswiG982QUbl1E_NCgI2liLfYoqJj_hIGCvldn-uuxz7mD2t7V68K6gsZYYR2r5tY1vpPowEm1pyFTObFA9EC-VHWEK_h2jxaQhzrEpqnYIjPrB90-MeGsdq7aP_jRPeB3w7q5mI4sxEN1io1fIub9u (Accessed Aug 6, 2026)
  3. https://practiceguides.chambers.com/practice-guides/corporate-ma-2026/japan/trends-and-developments (Accessed Aug 6, 2026)
  4. https://community.ionanalytics.com/mergermarket-ma-forum-japan-2026/agenda (Accessed Aug 6, 2026)
  5. https://www.cphi.com/media/44aea037/Japan-2026-market-facts-e5fae6faddedf623e453582d0328cb68.pdf (Accessed Aug 6, 2026)
  6. https://globalregulatorypartners.com/regulatory-revolution-in-japan-the-new-pathway-for-specific-use-drugs-in-2026/ (Accessed Aug 6, 2026)
  7. https://visionlifesciences.com/insights/japan-pharma-market-entry-guide (Accessed Aug 6, 2026)
  8. https://www.reuters.com/legal/transactional/bain-backed-tanabe-pharma-targets-three-new-drug-launches-year-japan-2026-05-14/ (Accessed Aug 6, 2026)
  9. https://www.aoshearman.com/en/insights/asia-pacific-dealmaking-fueled-by-strong-activity-in-japan-and-china (Accessed Aug 6, 2026)
  10. https://www.pmda.go.jp/english/int-activities/industry/0001.html? (Accessed Aug 6, 2026)
  11. https://www.pmda.go.jp/english/review-services/reviews/0003.html? (Accessed Aug 6, 2026)
  12. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000150542_00016.html? (Accessed Aug 6, 2026)
  13. https://www.ncc.go.jp/en/information/2026/0217/index.html? (Accessed Aug 6, 2026)
  14. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000068484.html? (Accessed Aug 6, 2026)
  15. https://www.ncc.go.jp/en/information/2026/0217/index.html? (Accessed Aug 6, 2026)
  16. https://www.pmda.go.jp/relief-services/0072.html? (Accessed Aug 6, 2026)
  17. https://firstwordpharma.com/story/4575499 (Accessed Aug 6, 2026)
  18. https://www.jetro.go.jp/en/invest/attractive_sectors/life_science/attractive_markets.html (Accessed Aug 6, 2026)
  19. https://www.takeda.com/newsroom/newsreleases/2017/takeda-announces-further-details-of-splitting-off-simple-absorption-type/ (Accessed Aug 6, 2026)
  20. https://www.drugpatentwatch.com/blog/the-sun-rises-again-a-strategic-history-of-the-japanese-pharmaceutical-industry-and-its-enduring-global-impact/ (Accessed Aug 6, 2026)
  21. https://www.ykbridge.net/blog/inside-japan-s-pharmaceutical-industry-market-size-key-players-and-future-trends (Accessed Aug 6, 2026)
  22. https://www.ykbridge.net/blog/inside-japan-s-pharmaceutical-industry-market-size-key-players-and-future-trends (Accessed Aug 6, 2026)
  23. https://www.jetro.go.jp/en/invest/attractive_sectors/life_science/attractive_markets.html (Accessed Aug 6, 2026)
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC8761953/ (Accessed Aug 6, 2026)
  25. https://www.nippon-shinyaku.co.jp/english/ir/Investor/pharmaceutical.php (Accessed Aug 6, 2026)
  26. https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals (Accessed Aug 6, 2026)
  27. https://www.cphi.com/media/44aea037/Japan-2025-infographic-Digital-4faaa4fddf375dad47025afee40b76ca.pdf (Accessed Aug 6, 2026)
  28. https://cmic-cro.com/en/why-japan/japan-market/ (Accessed Aug 6, 2026)
  29. https://pj.jiho.jp/article/254831 (Accessed Aug 6, 2026)
  30. https://www.cphi.com/media/44aea037/Japan-2026-market-facts-e5fae6faddedf623e453582d0328cb68.pdf (Accessed Aug 6, 2026)
  31. https://pj.jiho.jp/article/253283 (Accessed Aug 6, 2026)
  32. https://www.chugai-pharm.co.jp/english/news/detail/20260129170004_1224.html (Accessed Aug 6, 2026)
  33. https://www.fiercepharma.com/pharma/takeda-slimming-down-new-era-plots-4500-layoffs-latest-restructuring-drive (Accessed Aug 6, 2026)
  34. https://companiesmarketcap.com/inr/daiichi-sankyo/revenue/ (Accessed Aug 6, 2026)
  35. https://www.takeda.com/newsroom/newsreleases/2023/takeda-delivers-strong-revenue-and-profit-growth-in-fy2022-updated-capital-allocation-policy-reflects-deleveraging-progress-and-confidence-in-growth-outlook/ (Accessed Aug 6, 2026)
  36. https://www.biospace.com/deals/tanabe-pens-deal-to-sell-plants-to-towa-in-post-buyout-pivot (Accessed Aug 6, 2026)
  37. https://www.shionogi.com/global/en/news/2025/12/20251223_2.html (Accessed Aug 6, 2026)
  38. https://finance.yahoo.com/sectors/healthcare/articles/bain-backed-tanabe-pharma-targets-003551630.html (Accessed Aug 6, 2026)
  39. https://www.japantimes.co.jp/business/2026/03/26/companies/tanabe-pharma-licensing-deals-abroad/ (Accessed Aug 6, 2026)
  40. https://www.fiercepharma.com/marketing/tanabe-pharma-shifts-gears-bain-backed-future-dropping-mitsubishi-moniker-after-33b-deal (Accessed Aug 6, 2026)
  41. https://us.tanabe-pharma.com/about-us (Accessed Aug 6, 2026)
  42. https://www.baincapital.com/news/bain-capital-acquire-mitsubishi-tanabe-pharma-corporation (Accessed Aug 6, 2026)
  43. https://www.reuters.com/legal/transactional/bain-backed-tanabe-pharma-targets-three-new-drug-launches-year-japan-2026-05-14/ (Accessed Aug 6, 2026)
  44. https://trial.medpath.com/news/bain-backed-tanabe-pharma-targets-three-new-drug-launches-annually-in-japan-led-by-rare-disease-candidate (Accessed Aug 6, 2026)
  45. https://finance.yahoo.com/news/rare-disease-treatment-market-size-130000747.html (Accessed Aug 6, 2026)
  46. https://biosector.jp/the-tanabe-carve-out/ (Accessed Aug 6, 2026)
  47. https://www.tanabe-pharma.com/en/develop/pipeline.html (Accessed Aug 6, 2026)
  48. https://www.mcgc.com/english/ir/pdf/00885/00990.pdf (Accessed Aug 6, 2026)
  49. https://www.mcgc.com/english/csr/download/pdf/20_5_5_5.pdf (Accessed Aug 6, 2026)
  50. https://asia.nikkei.com/business/pharmaceuticals/japan-s-mitsubishi-chemical-weighs-sale-of-pharmaceutical-unit (Accessed Aug 6, 2026)
  51. https://www.tanabe-pharma.com/en/company/outline.html (Accessed Aug 6, 2026)
  52. https://www.mcgc.com/english/ir/pdf/01474/01715.pdf (Accessed Aug 6, 2026)
  53. https://www.mcgc.com/english/ir/pdf/01352/01548.pdf (Accessed Aug 6, 2026)
  54. https://www.mcgc.com/english/ir/pdf/02545/02790.pdf (Accessed Aug 6, 2026)
  55. https://www.mcgc.com/english/ir/pdf/02545/02790.pdf (Accessed Aug 6, 2026)
  56. https://medcitynews.com/2025/02/bain-capital-mitsubishi-tanabe-pharma-acquisition-chemicals-group-life-sciences/ (Accessed Aug 6, 2026)
  57. https://www.tanabe-pharma.com/en/develop/pipeline.html (Accessed Aug 6, 2026)
  58. Takeda Pharmaceuticals: Global Homepage (Accessed Aug 6, 2026)
  59. https://www.takeda.com/newsroom/newsreleases/2026/takeda-reports-first-quarter-fy2026-results/ (Accessed Aug 6, 2026)
  60. https://www.forbes.com/companies/takeda-pharmaceutical/ (Accessed Aug 6, 2026)
  61. https://www.takeda.com/newsroom/newsreleases/2026/takeda-transformation-strengthen-competitiveness-future-growth/ (Accessed Aug 6, 2026)
  62. https://firstwordpharma.com/story/7426046 (Accessed Aug 6, 2026)
  63. https://www.takeda.com/newsroom/newsreleases/2026/julie-kim-appointed-president-ceo-takeda/ (Accessed Aug 6, 2026)
  64. https://www.takeda.com/newsroom/newsreleases/2017/takeda-announces-further-details-of-splitting-off-simple-absorption-type/ (Accessed Aug 6, 2026)
  65. https://www.fiercepharma.com/pharma/takeda-slimming-down-new-era-plots-4500-layoffs-latest-restructuring-drive (Accessed Aug 6, 2026)
  66. https://www.takeda.com/newsroom/newsreleases/2023/takeda-delivers-strong-revenue-and-profit-growth-in-fy2022-updated-capital-allocation-policy-reflects-deleveraging-progress-and-confidence-in-growth-outlook/ (Accessed Aug 6, 2026)
  67. https://www.fiercebiotech.com/biotech/takeda-inks-17b-ai-discovery-deal-iambic-therapeutics (Accessed Aug 7, 2026)
  68. https://www.fiercepharma.com/pharma/takeda-gains-fda-nod-first-class-narcolepsy-treatment-orzeyful (Accessed Aug 7, 2026)
  69. https://www.businesswire.com/news/home/20260805760759/en/U.S.-FDA-Approves-Takedas-ORZEYFUL-oveporexton-the-First-and-Only-Medicine-to-Treat-the-Underlying-Cause-of-Narcolepsy-Type-1 (Accessed Aug 7, 2026)
  70. https://assets-dam.takeda.com/image/upload/v1785376660/Global/Investor/Financial-Results/FY2026/Q1/qr2026_q1_Pipeline_table_en.pdf (Accessed Aug 7, 2026)
  71. https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/ (Accessed Aug 7, 2026)
  72. https://www.biospace.com/press-releases/u-s-fda-approves-takedas-orzeyful-oveporexton-the-first-and-only-medicine-to-treat-the-underlying-cause-of-narcolepsy-type-1 (Accessed Aug 7, 2026)
  73. https://www.patientcareonline.com/view/fda-approves-oveporexton-first-orexin-receptor-agonist-for-narcolepsy-type-1 (Accessed Aug 7, 2026)
  74. https://www.iconplc.com/insights/blog/2026/06/05/japans-clinical-trial-transformation-building-global-future (Accessed Aug 7, 2026)
  75. https://www.pharmaceutical-technology.com/news/takeda-orzeyful-oveporexton-fda-approval-type-1-narcolepsy/ (Accessed Aug 7, 2026)
  76. https://www.takeda.com/ (Accessed Aug 7, 2026)
  77. https://www.takeda.com/newsroom/newsreleases/2026/oveporexton-phase-3-narcolepsy-type-1/ (Accessed Aug 7, 2026)
  78. https://markets.ft.com/data/announce/detail?dockey=600-202606151200BIZWIRE_USPRX____20260615_BW651327-1 (Accessed Aug 7, 2026)
  79. https://www.drugs.com/nda/oveporexton_260210.html (Accessed Aug 7, 2026)
  80. https://insights.citeline.com/pink-sheet/product-reviews/approvals/nod-for-oveporexton-in-second-market-as-japan-recommends-new-drugs-3Q4REPDSSBFVRO2OD3AWJ24JHA/ (Accessed Aug 7, 2026)
  81. https://www.alliedmarketresearch.com/press-release/narcolepsy-drugs-market.html (Accessed Aug 7, 2026)
  82. https://www.businesswire.com/news/home/20221013005667/en/Insights-on-the-Narcolepsy-Drugs-Global-Market-to-2027---by-Type-Disease-Type-Therapeutic-Type-and-Region---ResearchAndMarkets.com (Accessed Aug 7, 2026)
  83. https://www.novaoneadvisor.com/report/narcolepsy-therapeutics-market (Accessed Aug 7, 2026)
  84. https://www.alliedmarketresearch.com/press-release/narcolepsy-drugs-market.html (Accessed Aug 7, 2026)
  85. https://www.skyquestt.com/report/narcolepsy-drugs-market (Accessed Aug 7, 2026)
  86. https://www.mordorintelligence.com/industry-reports/narcolepsy-therapeutics-market (Accessed Aug 7, 2026)
  87. https://finance.yahoo.com/news/narcolepsy-market-reach-us-4-105500649.html (Accessed Aug 7, 2026)
  88. https://www.researchnester.com/reports/narcolepsy-drugs-market/2767 (Accessed Aug 7, 2026)
  89. https://www.expertmarketresearch.com/reports/narcolepsy-drugs-market (Accessed Aug 7, 2026)
  90. https://www.forbes.com/companies/takeda-pharmaceutical/ (Accessed Aug 7, 2026)
  91. https://www.fiercepharma.com/special-report/top-20-pharma-companies-by-2020-revenue (Accessed Aug 7, 2026)
  92. https://www.takeda.com/newsroom/newsreleases/2022/takeda-delivers-strong-fy2021-results-continued-growth-momentum-expected-in-fy2022/ (Accessed Aug 7, 2026)
  93. https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2021-revenue (Accessed Aug 10, 2026)
  94. https://www.pharmaceutical-technology.com/news/takeda-revenue-growth-fy2021/ (Accessed Aug 10, 2026)
  95. https://www.takeda.com/newsroom/newsreleases/2023/takeda-delivers-strong-revenue-and-profit-growth-in-fy2022-updated-capital-allocation-policy-reflects-deleveraging-progress-and-confidence-in-growth-outlook/ (Accessed Aug 10, 2026)
  96. https://www.contractpharma.com/top-company-profile/takeda/ (Accessed Aug 10, 2026)
  97. https://www.wallstreetzen.com/stocks/us/nyse/tak/revenue (Accessed Aug 10, 2026)
  98. https://www.statista.com/statistics/796960/takeda-pharmaceutical-revenue/?srsltid=AfmBOorGsr5STepY4ldP1rPwrHdN-s7r60v9MGOgZ3hAy-bSsAA4rNn8 (Accessed Aug 10, 2026)
  99. https://www.takeda.com/newsroom/newsreleases/2025/takeda-announces-fy2024-full-year-results-and-fy2025-outlook/ (Accessed Aug 10, 2026)
  100. https://www.takeda.com/newsroom/newsreleases/2025/takeda-delivers-strong-third-quarter-fy2024-results/ (Accessed Aug 10, 2026)
  101. https://www.takeda.com/newsroom/newsreleases/2026/takeda-reports-fourth-quarter-fy2025-results/ (Accessed Aug 10, 2026)
  102. https://pluang.com/en/news-feed/potensi-pipeline-takeda-harus-dibeli (Accessed Aug 10, 2026)
  103. https://companiesmarketcap.com/takeda-pharmaceutical/revenue/ (Accessed Aug 10, 2026)
  104. https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2025-revenue (Accessed Aug 10, 2026)
  105. https://pharmaphorum.com/oncology/daiichi-sankyo-gears-five-adc-launches-2026 (Accessed Aug 10, 2026)
  106. https://finance.yahoo.com/sectors/healthcare/articles/bull-case-daiichi-sankyo-company-043349148.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIeyTDKUk5iS_xrYc0CXmkswiG982QUbl1E_NCgI2liLfYoqJj_hIGCvldn-uuxz7mD2t7V68K6gsZYYR2r5tY1vpPowEm1pyFTObFA9EC-VHWEK_h2jxaQhzrEpqnYIjPrB90-MeGsdq7aP_jRPeB3w7q5mI4sxEN1io1fIub9u (Accessed Aug 10, 2026)
  107. https://www.japantimes.co.jp/business/2026/05/12/companies/daiichi-sankyo-new-cancer-drugs/ (Accessed Aug 10, 2026)
  108. https://www.businesswire.com/news/home/20260730555689/en/Daiichi-Sankyo-Reports-First-Quarter-Fiscal-Year-2026-Financial-Results (Accessed Aug 10, 2026)
  109. https://www.merck.com/news/merck-statement-on-daiichi-sankyo-update-to-manufacturing-and-supply-plan/ (Accessed Aug 10, 2026)
  110. https://www.merck.com/news/ifinatamab-deruxtecan-granted-priority-review-in-the-u-s-for-adult-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer-who-experienced-disease-progression-on-or-after-platinum-bas/ (Accessed Aug 12, 2026)
  111. https://www.merck.com/wp-content/uploads/sites/124/2026/08/2Q26-Merck-Earnings-Presentation.pdf (Accessed Aug 12, 2026)
  112. https://www.pearceip.law/2026/04/13/daiichi-sankyo-msds-ifinatamab-deruxtecan-granted-fda-priority-review/ (Accessed Aug 12, 2026)
  113. https://www.biospace.com/drug-development/patient-deaths-put-merck-daiichi-sankyos-antibody-drug-conjugate-on-hold (Accessed Aug 12, 2026)
  114. https://www.biospace.com/drug-development/daiichi-emerges-from-bruising-2-years-with-vision-for-cracking-cancers-big-leagues
  115. https://www.msd.com/news/msd-statement-on-daiichi-sankyo-update-to-manufacturing-and-supply-plan/ (Accessed Aug 12, 2026)
  116. https://www.merck.com/news/ifinatamab-deruxtecan-granted-priority-review-in-the-u-s-for-adult-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer-who-experienced-disease-progression-on-or-after-platinum-bas/ (Accessed Aug 12, 2026)
  117. https://www.bioprocessintl.com/deal-making/az-inks-6-9bn-adc-deal-with-daiichi-sankyo (Accessed Aug 12, 2026)
  118. https://www.reuters.com/business/healthcare-pharmaceuticals/daiichi-sankyo-merck-team-up-22-bln-collaboration-sankyos-antibody-drug-2023-10-19/ (Accessed Aug 12, 2026)
  119. https://www.precisionmedicineonline.com/precision-oncology/astrazeneca-readying-breast-cancer-franchise-growth-led-enhertu-datroway (Accessed Aug 12, 2026)
  120. https://www.biopharminternational.com/view/datroway-eu-approval-first-line-metastatic-tnbc (Accessed Aug 12, 2026)
  121. https://www.reuters.com/business/healthcare-pharmaceuticals/daiichi-sankyo-merck-team-up-22-bln-collaboration-sankyos-antibody-drug-2023-10-19/ (Accessed Aug 12, 2026)
  122. https://www.spglobal.com/market-intelligence/en/news-insights/articles/2021/3/cancer-drugs-show-big-sales-rise-in-2020-abbvie-s-humira-again-tops-list-63249898 (Accessed Aug 12, 2026)
  123. https://www.echemi.com/cms/145925.html (Accessed Aug 12, 2026)
  124. https://www.fiercepharma.com/special-reports/top-20-drugs-worldwide-sales-2021 (Accessed Aug 13, 2026)
  125. https://pharmashots.com/16032/top-20-oncology-companies-based-on-2022-by-total-revenue/ (Accessed Aug 13, 2026)
  126. https://www.proclinical.com/blogs/2024-9/who-are-the-top-10-oncology-companies-in-the-world-2024 (Accessed Aug 13, 2026)
  127. https://www.oncologynewscentral.com/article/new-oncology-drug-market-reports-drop (Accessed Aug 13, 2026)
  128. https://www.statista.com/chart/35651/distribution-of-global-pharma-revenue-by-drug-type/?srsltid=AfmBOorU6O7J9jQp8zE7Y1VLqqmlEMIvLb7BdqdHuV82Efd9eQ4Ns_U9 (Accessed Aug 13, 2026)
  129. https://www.statista.com/chart/35651/distribution-of-global-pharma-revenue-by-drug-type/?srsltid=AfmBOopIjYnQFaaTPfankG6cDzNMPi3dB0pDQP3sd0J4_aol4zGb76N_(Accessed Aug 13, 2026)
  130. https://clival.com/blog/10-best-selling-cancer-drugs-by-estimated-global-sales-2025-2026 (Accessed Aug 13, 2026)
  131. https://in.investing.com/pro/TSE:4568/explorer/total_rev (Accessed Aug 13, 2026)
  132. https://www.daiichisankyo.com/files/investors/library/quarterly_result/2020/pdf/FY2020_Q4_Financial_Results_E.pdf (Accessed Aug 13, 2026)
  133. https://www.drugdiscoverytrends.com/2021-pharma50/daiichi-sankyo/ (Accessed Aug 13, 2026)
  134. https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/2021/VR2021_EN_P93-111.pdf (Accessed Aug 13, 2026)
  135. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf (Accessed Aug 13, 2026)
  136. https://www.daiichisankyo.com/files/rd/pipeline/index/pdf/202607_Pipeline_E.pdf (Accessed Aug 13, 2026)
  137. https://www.theworldfolio.com/company/astellas-pharma-inc/1583/ (Accessed Aug 13, 2026)
  138. https://pharmaboardroom.com/articles/top-10-pharma-companies-in-japan/ (Accessed Aug 13, 2026)
  139. https://newsroom.astellas.com/news?l=100 (Accessed Aug 13, 2026)
  140. https://newsroom.astellas.com/news?l=10 (Accessed Aug 13, 2026)
  141. https://newsroom.astellas.com/2026-08-07-submission-of-new-drug-application-for-fezolinetant-in-japan-for-the-treatment-of-vasomotor-symptoms-associated-with-menopause (Accessed Aug 13, 2026)
  142. https://www.thepharmaletter.com/pharma-news/strong-2024-for-astellas-as-vyloy-momentum-builds (Accessed Aug 13, 2026)
  143. https://pharmaphorum.com/news/astellas-raises-padcev-forecasts-bladder-cancer-data (Accessed Aug 13, 2026)
  144. https://www.prnewswire.com/news-releases/japans-ministry-of-health-labour-and-welfare-approves-padcev-enfortumab-vedotin-with-keytruda-pembrolizumab-for-first-line-treatment-of-radically-unresectable-urothelial-carcinoma-302255539.html (Accessed Aug 13, 2026)
  145. https://www.prnewswire.com/news-releases/astellas-announces-five-year-corporate-strategic-plan-to-deliver-greater-value-faster-for-patients-and-position-itself-as-a-sustainable-growth-company-302781231.html (Accessed Aug 13, 2026)
  146. https://content.edgar-online.com/ExternalLink/EDGAR/0001060736-20-000035.html?hash=70b3b2cdd74d69aa0e994fb9c36a545ba3baf592144ec611e86caaa8e85fd1dc&dest=exhibit10110q2020q3_htm#exhibit10110q2020q3_htm (Accessed Aug 13, 2026)
  147. https://www.fool.com/earnings/call-transcripts/2021/02/12/seattle-genetics-sgen-q4-2020-earnings-call-transc/ (Accessed Aug 13, 2026)
  148. https://www.nasdaq.com/press-release/seagen-reports-fourth-quarter-and-full-year-2021-financial-results-2022-02-09 (Accessed Aug 13, 2026)
  149. https://firstwordpharma.com/story/5706841 (Accessed Aug 13, 2026)
  150. https://www.businesswire.com/news/home/20230215005723/en/Seagen-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results (Accessed Aug 14, 2026)
  151. https://www.sec.gov/Archives/edgar/data/1060736/000106073623000045/ex-9912023q3.htm (Accessed Aug 14, 2026)
  152. https://www.biochempeg.com/article/389.html (Accessed Aug 14, 2026)
  153. https://www.echemi.com/cms/2241569.html (Accessed Aug 14, 2026)
  154. https://annualreview.pfizer.com/2024/ (Accessed Aug 14, 2026)
  155. https://annualreview.pfizer.com/ (Accessed Aug 14, 2026)
  156. https://www.fiercepharma.com/pharma/astellas-counts-new-medicines-offset-projected-xtandi-decline-fiscal-2026 (Accessed Aug 14, 2026)
  157. https://pulse2.com/pfizer-raises-2026-revenue-guidance-by-500-million-as-non-covid-products-outperform-by-1-5-billion/ (Accessed Aug 14, 2026)
  158. https://pulse2.com/pfizer-raises-2026-revenue-guidance-by-500-million-as-non-covid-products-outperform-by-1-5-billion/ (Accessed Aug 14, 2026)
  159. https://qz.com/pfizer-builds-oncology-growth-around-padcev-and-pipeline-expansion (Accessed Aug 14, 2026)
  160. https://newsroom.astellas.com/2026-02-24-astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-r-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer (Accessed Aug 14, 2026)
  161. https://www.pharmexec.com/view/astellas-enters-billion-global-collaboration-vir-biotechnology-advance-psma-targeting-pro-xten (Accessed Aug 14, 2026)
  162. https://www.fiercepharma.com/special-report/top-20-pharma-companies-by-2020-revenue (Accessed Aug 14, 2026)
  163. https://www.astellas.com/content/dam/astellas-com/global/en/documents/financial-results/1q-fy2020-financial-results-en.pdf (Accessed Aug 14, 2026)
  164. https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2021-revenue (Accessed Aug 14, 2026)
  165. https://companiesmarketcap.com/astellas-pharma/revenue/ (Accessed Aug 14, 2026)
  166. https://companiesmarketcap.com/inr/astellas-pharma/revenue/ (Accessed Aug 14, 2026)
  167. https://www.perplexity.ai/finance/4503.T?trk=public_post_comment-text (Accessed Aug 14, 2026)
  168. https://in.marketscreener.com/quote/stock/ASTELLAS-PHARMA-INC-6491262/finances/ (Accessed Aug 14, 2026)
  169. https://www.drugdiscoverytrends.com/pharma-50-the-50-largest-pharmaceutical-companies-in-the-world-for-2025/ (Accessed Aug 14, 2026)
  170. https://www.statista.com/statistics/825549/astellas-pharma-inc-revenue/?srsltid=AfmBOop4hCoyVifqc1ReEtgMMZ1k9ImbSwhT6TH0Sw7Bsri2Q68wP3qk (Accessed Aug 14, 2026)
  171. https://www.investing.com/news/company-news/astellas-fy2025-slides-revenue-tops-21t-core-profit-surges-42-93CH-4639530 (Accessed Aug 14, 2026)
  172. https://www.investing.com/news/transcripts/earnings-call-transcript-astellas-pharmas-record-fy2025-growth-in-q4-2026-93CH-4639522 (Accessed Aug 14, 2026)
  173. https://finance.yahoo.com/quote/ALPMF/earnings/ALPMF-Q4-2026-earnings_call-537117.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIeyTDKUk5iS_xrYc0CXmkswiG982QUbl1E_NCgI2liLfYoqJj_hIGCvldn-uuxz7mD2t7V68K6gsZYYR2r5tY1vpPowEm1pyFTObFA9EC-VHWEK_h2jxaQhzrEpqnYIjPrB90-MeGsdq7aP_jRPeB3w7q5mI4sxEN1io1fIub9u (Accessed Aug 14, 2026)
  174. https://quartr.com/companies/astellas-pharma-inc_15700 (Accessed Aug 14, 2026)
  175. https://www.astellas.com/en/science/research-and-development/pipeline (Accessed Aug 14, 2026)
  176. https://www.chugai-pharm.co.jp/english/news/ (Accessed Aug 14, 2026)
  177. https://www.chugai-pharm.co.jp/english/news/detail/20260724160000_1265.html (Accessed Aug 14, 2026)
  178. https://www.chugai-pharm.co.jp/english/news/detail/20260424170002_1247.html (Accessed Aug 14, 2026)
  179. https://www.biospace.com/press-releases/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-developments (Accessed Aug 14, 2026)
  180. https://pj.jiho.jp/article/254807 (Accessed Aug 14, 2026)
  181. https://pj.jiho.jp/article/254807 (Accessed Aug 14, 2026)
  182. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-first-quarter-2026-financial (Accessed Aug 14, 2026)
  183. https://www.chugai-pharm.co.jp/english/news/detail/20210204170004_800.html (Accessed Aug 14, 2026)
  184. https://www.chugai-pharm.co.jp/english/news/detail/20220203170005_893.html (Accessed Aug 14, 2026)
  185. https://nz.finance.yahoo.com/quote/CHGCF/financials/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIeyTDKUk5iS_xrYc0CXmkswiG982QUbl1E_NCgI2liLfYoqJj_hIGCvldn-uuxz7mD2t7V68K6gsZYYR2r5tY1vpPowEm1pyFTObFA9EC-VHWEK_h2jxaQhzrEpqnYIjPrB90-MeGsdq7aP_jRPeB3w7q5mI4sxEN1io1fIub9u
  186. https://www.chugai-pharm.co.jp/english/news/detail/20230202163003_965.html (Accessed Aug 14, 2026)
  187. https://www.chugai-pharm.co.jp/english/news/detail/20240201170004_1044.html (Accessed Aug 14, 2026)
  188. https://www.chugai-pharm.co.jp/english/news/detail/20250130170004_1134.html (Accessed Aug 14, 2026)
  189. https://www.chugai-pharm.co.jp/english/news/detail/20260129170004_1224.html (Accessed Aug 14, 2026)
  190. https://www.chugai-pharm.co.jp/english/profile/about/outline.html (Accessed Aug 14, 2026)
  191. https://www.chugai-pharm.co.jp/english/news/detail/20260129170004_1224.html (Accessed Aug 14, 2026)
  192. https://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline/files/260724ePipeline.pdf (Accessed Aug 19, 2026)
  193. https://otsukapharma.in/ (Accessed Aug 19, 2026)
  194. https://www.otsuka-us.com/ (Accessed Aug 19, 2026)
  195. https://www.otsuka.com/en/company/history/detaile/ (Accessed Aug 19, 2026)
  196. https://www.otsuka.co.jp/en/company/newsreleases/ (Accessed Aug 19, 2026)
  197. https://www.otsuka.co.jp/en/company/newsreleases/2026/20260615_1.html (Accessed Aug 19, 2026)
  198. https://transcendtherapeutics.com/otsuka-pharmaceutical-to-acquire-transcend-therapeutics/ (Accessed Aug 19, 2026)
  199. https://www.otsuka.co.jp/en/company/newsreleases/2026/20260615_1.html (Accessed Aug 19, 2026)
  200. https://transcendtherapeutics.com/otsuka-pharmaceutical-to-acquire-transcend-therapeutics/ (Accessed Aug 19, 2026)
  201. https://www.technavio.com/report/post-traumatic-stress-disorder-therapeutics-market-industry-analysis (Accessed Aug 19, 2026)
  202. https://www.businesswire.com/news/home/20200309005077/en/Global-Post-traumatic-Stress-Disorder-PSTD-Therapeutics-Market-2020-2024-Evolving-Opportunities-with-AstraZeneca-Plc-and-Azevan-Pharmaceuticals-Inc.-Technavio (Accessed Aug 19, 2026)
  203. https://www.prnewswire.com/news-releases/post-traumatic-stress-disorder-treatment-market-to-reach-26-1-bn-globally-by-2031-at-4-9-cagr-allied-market-research-301593174.html (Accessed Aug 19, 2026)
  204. https://gettherapybirmingham.com/blog/the-great-shift-why-the-market-is-moving-from-cbt-to-somatic-and-neuro-experiential-therapies-for-trauma/ (Accessed Aug 19, 2026)
  205. https://www.biospace.com/post-traumatic-stress-disorder-market-size-to-reach-us-3-2-billion-by-2034-impelled-by-mindfulness-based-interventions (Accessed Aug 19, 2026)
  206. https://www.otsuka.com/en/ir/library/pdf/annual/2021_07.pdf (Accessed Aug 19, 2026)
  207. https://www.drugdiscoverytrends.com/2022-pharma50/otsuka-holdings-pharmaceutical-business/ (Accessed Aug 19, 2026)
  208. https://www.drugdiscoverytrends.com/2021-pharma50/otsuka-holdings-pharmaceutical-business/ (Accessed Aug 19, 2026)
  209. https://www.otsuka.com/en/ir/individual/ataglance.html (Accessed Aug 19, 2026)
  210. https://www.smartkarma.com/insights/otsuka-holdings-4578-jp-strong-2022-result-2023-revenue-to-hit-record-high-thanks-to-key-drugs (Accessed Aug 19, 2026)
  211. https://www.otsuka.com/en/ir/individual/ataglance.html (Accessed Aug 19, 2026)
  212. https://pestel-analysis.com/blogs/owners/otsuka (Accessed Aug 19, 2026)
  213. https://www.otsuka.com/en/ir/individual/ataglance.html (Accessed Aug 19, 2026)
  214. https://www.drugdiscoverytrends.com/2025-pharma50/otsuka-holdings/ (Accessed Aug 19, 2026)
  215. https://www.otsuka.com/en/ir/individual/ataglance.html (Accessed Aug 19, 2026)
  216. https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/219826/otsuka-holdings-posts-profit-surge-in-2025-but-guides-to-lower-earnings-in-2026/ (Accessed Aug 19, 2026)
  217. https://umbrex.com/resources/company-profiles/otsuka-holdings-co-ltd/ (Accessed Aug 19, 2026)
  218. https://ssl4.eir-parts.net/doc/4578/ir_material7/283040/00.pdf (Accessed Aug 19, 2026)
  219. https://www.peptidream.com/en/ (Accessed Aug 20, 2026)
  220. https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4012024:0-peptidream-six-new-clinical-programs-and-30-pet-revenue-growth-drive-robust-h1-2026-performance/ (Accessed Aug 20, 2026)
  221. https://www.investing.com/news/company-news/peptidream-h1-2026-slides-clinical-pipeline-surges-loss-narrows-93CH-4855858 (Accessed Aug 20, 2026)
  222. https://www.peptidream.com/en/ (Accessed Aug 20, 2026)
  223. https://www.openpr.com/news/4606120/japan-nuclear-medicine-market-gains-momentum-as (Accessed Aug 20, 2026)
  224. https://www.curiumpharma.com/2026/06/11/completion-clinical-tiral-japan/ (Accessed Aug 20, 2026)
  225. https://www.morningstar.com/news/business-wire/20260611415075/peptidream-pdradiopharma-and-curium-group-announce-completion-of-patient-dosing-in-clinical-trial-of-64cu-psma-it-for-prostate-cancer-in-japan (Accessed Aug 20, 2026)
  226. https://firstwordpharma.com/story/6321753 (Accessed Aug 20, 2026)
  227. https://www.curiumpharma.com/2026/02/04/patient-japan-psma-prostate-cancer/ (Accessed Aug 20, 2026)
  228. https://www.globenewswire.com/news-release/2026/02/04/3231755/0/en/curium-group-peptidream-and-pdradiopharma-enroll-first-patient-to-registrational-clinical-trial-of-lu-psma-i-t-for-prostate-cancer-in-japan.html (Accessed Aug 20, 2026)
  229. https://www.ncc.go.jp/en/information/press_release/2026/0702/index.html (Accessed Aug 20, 2026)
  230. https://allsci.com/news/clinical-trials/peptidreams-cldn18-2-radiopharmaceutical-enters-first-in-human-study-in-gastric-cancer/ (Accessed Aug 20, 2026)
  231. https://www.businesswire.com/news/home/20260611581194/en/PeptiDream-Announces-First-Dosing-of-Claudin18.2-Targeting-Radiopharmaceutical-Candidate-64Cu-PD-29875-in-Patients-with-Gastric-Cancer (Accessed Aug 20, 2026)
  232. https://finance.biggo.com/news/ir_4587.T_20260611_d03f23473a4b (Accessed Aug 20, 2026)
  233. https://www.peptidream.com/en/pipeline/ (Accessed Aug 21, 2026)
  234. https://companiesmarketcap.com/peptidream/revenue/ (Accessed Aug 21, 2026)
  235. https://stockanalysis.com/quote/tyo/4587/revenue/ (Accessed Aug 21, 2026)
  236. https://stockanalysis.com/quote/tyo/4587/revenue/ (Accessed Aug 21, 2026)
  237. https://the-shashi.com/en/tse/4587/financials/ (Accessed Aug 21, 2026)
  238. https://the-shashi.com/en/tse/4587/ (Accessed Aug 21, 2026)
  239. https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:2845869:0-peptidream-pipeline-doubled-to-13-clinical-programs-fy2025-revenue-missed-forecasts-but-radiopharma-sales-strong/ (Accessed Aug 21, 2026)
  240. https://prismbiolab.com/news/phase-1-clinical-research-results-of-e7386-jointly-created-by-prismbiolab-and-eisai-published-in-esmo-open/ (Accessed Aug 24, 2026)
  241. https://www.prnewswire.com/news-releases/prism-biolab-and-receptorai-announce-drug-discovery-collaboration-agreement-302712182.html (Accessed Aug 24, 2026)
  242. https://www.prnewswire.com/news-releases/prism-biolab-and-receptorai-announce-drug-discovery-collaboration-agreement-302712182.html (Accessed Aug 24, 2026)
  243. https://prismbiolab.com/news/phase-1-clinical-research-results-of-e7386-jointly-created-by-prismbiolab-and-eisai-published-in-esmo-open/ (Accessed Aug 24, 2026)
  244. https://prismbiolab.com/en/news/20260608_news/ (Accessed Aug 24, 2026)
  245. https://www.businesswire.com/news/home/20251216295669/en/Talus-Bio-Announces-New-Collaboration-with-PRISM-BioLab-to-Discover-Novel-Modulators-of-Transcription-Factor-and-Protein-Protein-Interaction-Targets (Accessed Aug 24, 2026)
  246. https://www.prnewswire.com/news-releases/prism-biolab-achieved-initial-milestone-and-receives-the-milestone-payment-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-302615292.html (Accessed Aug 24, 2026)
  247. https://www.esmoopen.com/article/S2059-7029(25)01762-4/fulltext (Accessed Aug 24, 2026)
  248. https://www.zoominfo.com/c/prism-biolab-co-ltd/353620987 (Accessed Aug 24, 2026)
  249. https://growjo.com/company/PRISM_BioLab_Co._Ltd. (Accessed Aug 24, 2026)
  250. https://www.preqin.com/data/profile/asset/prism-biolab-co---ltd-/115263 (Accessed Aug 24, 2026)
  251. https://www.tipranks.com/stocks/jp:206a/stock-analysis (Accessed Aug 24, 2026)
  252. https://holistic-r.org/adm/wp-content/uploads/2024/07/211A240719_en.pdf (Accessed Aug 24, 2026)
  253. https://multiples.vc/public-comps/prism-biolab-valuation-multiples (Accessed Aug 24, 2026)
  254. https://nz.finance.yahoo.com/quote/206A.T/financials/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIeyTDKUk5iS_xrYc0CXmkswiG982QUbl1E_NCgI2liLfYoqJj_hIGCvldn-uuxz7mD2t7V68K6gsZYYR2r5tY1vpPowEm1pyFTObFA9EC-VHWEK_h2jxaQhzrEpqnYIjPrB90-MeGsdq7aP_jRPeB3w7q5mI4sxEN1io1fIub9u (Accessed Aug 24, 2026)
  255. https://www.marketwatch.com/investing/stock/206a/company-profile?countrycode=jp (Accessed Aug 24, 2026)
  256. https://www.marketscreener.com/news/prism-biolab-co-ltd-reports-earnings-results-for-the-full-year-ended-september-30-2025-ce7e5adbdd80f224 (Accessed Aug 24, 2026)
  257. https://www.zoiccs.co.jp/cms/wp-content/themes/prism_snow-monkey/data/pdf/206A.pdf?utm (Accessed Aug 24, 2026)
  258. https://prismbiolab.com/en/ir/performance/?utm (Accessed Aug 24, 2026)
  259. https://prismbiolab.com/en/pipeline/ (Accessed Aug 24, 2026)
  260. https://heartseed.jp/en/ (Accessed Aug 25, 2026)
  261. https://heartseed.jp/en/technology.html (Accessed Aug 25, 2026)
  262. https://heartseed.jp/en/management.html (Accessed Aug 25, 2026)
  263. https://www.biospace.com/press-releases/heartseed-worlds-first-clinical-trial-of-catheter-administration-of-ipsc-derived-cardiomyocyte-spheroids-first-patient-dosed (Accessed Aug 25, 2026)
  264. https://heartseed.jp/en/news.html (Accessed Aug 25, 2026)
  265. https://finance.biggo.com/news/QPELhp4BLfE1EzqPyrMR (Accessed Aug 25, 2026)
  266. https://pmc.ncbi.nlm.nih.gov/articles/PMC11633416/ (Accessed Aug 25, 2026)
  267. https://finance.biggo.com/news/QPELhp4BLfE1EzqPyrMR (Accessed Aug 25, 2026)
  268. https://theregenreport.com/2026/06/27/heartseed-doses-first-patient-in-historic-ipsc-derived-cardiomyocyte-trial-via-catheter/ (Accessed Aug 25, 2026)
  269. https://heartseed.jp/en/index.html#pipeline (Accessed Aug 25, 2026)
  270. https://pitchbook.com/profiles/company/234023-41#overview (Accessed Aug 25, 2026)
  271. https://www.nikon.com/company/news/2026/0612_01/ (Accessed Aug 25, 2026)
  272. https://www.marketscreener.com/news/heartseed-inc-provides-non-consolidated-earnings-guidance-for-the-fiscal-year-ending-december-31-2-ce7858dad98ef226 (Accessed Aug 25, 2026)
  273. https://finance.biggo.com/news/jpx_tdnet_140120260216562988 (Accessed Aug 25, 2026)
  274. https://www.wsj.com/market-data/quotes/JP/XTKS/219A/financials/annual/income-statement (Accessed Aug 25, 2026)
  275. https://finance.biggo.com/news/JP_4883.T_2026-08-21 (Accessed Aug 31, 2026)
  276. https://crisprmedicinenews.com/press-release-service/card/modalis-announces-publication-in-human-gene-therapy-of-study-demonstrating-efficient-lama1-gene-acti/ (Accessed Aug 31, 2026)
  277. https://crisprmedicinenews.com/press-release-service/card/modalis-therapeutics-reports-data-supporting-development-of-a-transformative-epigenome-editing-thera/ (Accessed Aug 31, 2026)
  278. https://crisprmedicinenews.com/news/modalis-partners-with-solve-fshd-to-develop-crispr-therapy-for-facioscapulohumeral-muscular-dystroph/ (Accessed Aug 31, 2026)
  279. https://modalistx.com/en/ (Accessed Aug 31, 2026)
  280. https://modalistx.com/en/ir/faq/ (Accessed Aug 31, 2026)
  281. https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3863109/modalis-revises-interim-results-after-rd-expense-timing-error/ (Accessed Aug 31, 2026)
  282. https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3863107/modalis-therapeutics-issues-further-corrections-to-interim-financial-results/ (Accessed Sept 1, 2026)
  283. https://www.daiwair.co.jp/td_download.cgi?c=4883&i=2194940 (Accessed Sept 1, 2026)
  284. https://modalistx.com/en/ir/performance/ (Accessed Sept 1, 2026)
  285. https://www.businesswire.com/news/home/20201104005831/en/Modalis-Therapeutics-Reports-Third-Quarter-2020-Financial-Results-and-Operational-Highlights (Accessed Sept 1, 2026)
  286. https://www.businesswire.com/news/home/20200827005034/en/Modalis-Therapeutics-Reports-Second-Quarter-2020-Financial-Results-and-Operational-Highlights (Accessed Sept 1, 2026)
  287. https://www.businesswire.com/news/home/20200827005034/en/Modalis-Therapeutics-Reports-Second-Quarter-2020-Financial-Results-and-Operational-Highlights (Accessed Sept 1, 2026)
  288. https://modalistx.com/en/ir/performance/ (Accessed Sept 1, 2026)
  289. https://www.reuters.com/markets/companies/4883.T/financials/title_/income-annual/ (Accessed Sept 1, 2026)
  290. https://netnetmarket.com/stock/symbol/4883.T/financial (Accessed Sept 1, 2026)
  291. https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/200469/modalis-posts-wider-losses-in-2025-with-no-revenue-and-no-2026-guidance/ (Accessed Sept 1, 2026)
  292. https://finance.biggo.com/quote/4883.T/earnings-call/JP_4883.T_2026-08-21 (Accessed Sept 1, 2026)
  293. https://modalistx.com/en/business/pipeline/ (Accessed Sept 1, 2026)
  294. https://www.japantimes.co.jp/news/2024/07/30/japan/science-health/japan-drug-loss/ (Accessed Sept 1, 2026)
  295. https://www.startupblink.com/top-startups/japan/healthtech/pharmaceuticals (Accessed Sept 1, 2026)
  296. https://www.f6s.com/companies/pharmaceuticals/japan/co (Accessed Sept 1, 2026)
  297. https://www.f6s.com/company/acuris-pharma#about (Accessed Sept 1, 2026)
  298. https://visionlifesciences.com/insights/japan-pharma-market-entry-guide (Accessed Sept 1, 2026)
  299. https://intuitionlabs.ai/articles/japan-drug-approval-process (Accessed Sept 1, 2026)
  300. https://www.biospectrumasia.com/analysis/26/27045/japan-pushes-startups-to-power-the-next-biotech-cycle.html (Accessed Sept 1, 2026)
  301. https://www.f6s.com/companies/pharmaceuticals/japan/co (Accessed Sept 1, 2026)
  302. https://www.biospace.com/press-releases/j-pharma-co-ltd-and-uniphar-announce-advancement-of-nanvuranlat-into-phase-3-clinical-development-following-fda-alignment-and-initial-patient-enrollment (Accessed Sept 2, 2026)
  303. https://pmlive.com/pmhub/uniphar/j-pharma-co-ltd-and-uniphar-announce-advancement-of-nanvuranlat-into-phase-3-clinical-development-following-fda-alignment-and-initial-patient-enrollment/ (Accessed Sept 2, 2026)
  304. https://www.j-pharma.com/en/ir/message/ (Accessed Sept 2, 2026)
  305. https://www.nomuraholdings.com/en/news/nr/news20250409.html (Accessed Sept 2, 2026)
  306. Chordia Therapeutics (TYO:190A) Company Profile & Description (Accessed Sept 2, 2026)
  307. https://www.chordiatherapeutics.com/en/news/news1006071840021750449/main/0/link/EN_20260105_CMO_final.pdf (Accessed Sept 2, 2026)
  308. https://www.nxera.life/pipeline (Accessed Sept 2, 2026)
  309. https://www.biospace.com/press-releases/nxera-pharma-operational-highlights-and-consolidated-results-for-the-second-quarter-2026 (Accessed Sept 2, 2026)
  310. https://firstwordpharma.com/story/5922636 (Accessed Sept 2, 2026)
  311. https://www.irstreet.com/new/en/brand/index.php?&contents=brand_newsrelease&brand=209 (Accessed Sept 2, 2026)
  312. https://finance.biggo.com/news/51tLSZsBnz5vdl4ArCmv (Accessed Sept 2, 2026)
  313. https://genemod.net/blog/top-10-biotech-companies-in-japan-to-watch-leading-into-2026 (Accessed Sept 2, 2026)
  314. https://dimensionmarketresearch.com/report/japan-regenerative-medicine-market/ (Accessed Sept 2, 2026)
  315. https://www.labiotech.eu/best-biotech/japan-hottest-biotech-healthcare/ (Accessed Sept 2, 2026)
  316. https://in.investing.com/news/company-news/sanbio-fy2026-slides-losses-widen-as-akuugo-launch-nears-93CH-5307775 (Accessed Sept 2, 2026)
  317. https://quartr.com/companies/sanbio-company-limited_21523 (Accessed Sept 2, 2026)
  318. https://pj.jiho.jp/article/256239 (Accessed Sept 2, 2026)
  319. https://in.investing.com/news/transcripts/earnings-call-transcript-sanbio-q4-2026-shows-eps-improvement-stock-up-93CH-5307747 (Accessed Sept 2, 2026)
  320. https://www.investing.com/news/company-news/sanbio-fy2026-slides-losses-widen-as-akuugo-launch-nears-93CH-4580375 (Accessed Sept 2, 2026)
  321. https://www.chordiatherapeutics.com/en/ir/finance/highlight.html (Accessed Sept 2, 2026)
  322. https://data.swcms.net/file/chordiatherapeutics/dam/jcr:9cc46cc5-6da9-49dd-9557-02dfac91603b/140120241015598115.pdf (Accessed Sept 2, 2026)
  323. https://www.alphaspread.com/security/tse/190a/financials/income-statement/revenue (Accessed Sept 2, 2026)
  324. https://finance.logmi.jp/en/articles/383071 (Accessed Sept 2, 2026)
  325. https://www.sec.gov/Archives/edgar/data/1839970/000119312526306506/d98958ds1.htm (Accessed Sept 2, 2026)
  326. https://www.chordiatherapeutics.com/en/ir/new-faq.html (Accessed Sept 2, 2026)
  327. https://www.nature.com/articles/d43747-022-00077-7 (Accessed Sept 2, 2026)
  328. https://www.chordiatherapeutics.com/en/science/pipeline.html (Accessed Sept 2, 2026)

Pharma Insight Reports

https://adisinsight.springer.com/insight-hub